BioVie Documents

BioVie SEC Filings

BioVie Documents 2026

BioVie Stock analysis

BioVie BioVie, Inc. generates revenue through the development and marketing of drug therapies for liver disease and neurodegenerative conditions. The company focuses on two primary drug candidates: BIV201, an orphan drug for refractory ascites due to liver cirrhosis, administered as a liquid formulation, and NE3107, an orally administered small molecule targeting neuroinflammation and insulin resistance. BIV201 is developed for liver disease treatment, while NE3107 addresses neurodegenerative disease by inhibiting inflammatory activation of ERK and NFkB pathways without disrupting their homeostatic functions. The company markets these therapies directly to healthcare providers and institutions specializing in liver and neurodegenerative disorders. BioVie's revenue streams are derived from the commercialization of BIV201 and NE3107, with BIV201 currently in development for refractory ascites in liver cirrhosis patients. The firm targets medical professionals and institutions focused on liver disease management and neurodegenerative research. NE3107 is positioned as a treatment for conditions involving inflammation-driven insulin resistance, appealing to healthcare systems managing metabolic and neurological disorders. The company’s product portfolio is tailored to niche therapeutic areas with unmet medical needs, particularly in liver and neurodegenerative conditions. The company’s business model relies on the progression of BIV201 and NE3107 through clinical development stages toward regulatory approval and market entry. BIV201 is an orphan drug candidate, which may benefit from regulatory incentives for rare diseases, while NE3107 targets a broader patient population affected by neuroinflammation. BioVie’s revenue potential is tied to the successful advancement of these drug candidates into commercialization, with no current revenue streams disclosed beyond development-stage activities.